|MDACC Study No:||2011-0167 (clinicaltrials.gov NCT No: NCT01323751)|
|Title:||A Phase I/II, Open-label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed-Refractory Multiple Myeloma|
|Principal Investigator:||Robert Orlowski|
|Treatment Agent:||ACY-1215; Bortezomib; Dexamethasone|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of ACY-1215 (ricolinostat) that can be given alone and in combination with
dexamethasone and Velcade (bortezomib) to patients with MM. The safety of this
drug combination will also be studied.
Part 1 of this study, where patients were given ACY-1215 alone, has ended.
Parts 2 and 3, where ACY-1215 is given with dexamethasone and bortezomib are
still ongoing. Part 2 enrollment will be completed before Part 3 begins.